Immunohistochemistry of estrogen and progesterone receptors reconsidered - Experience with 5,993 breast cancers

被引:344
作者
Nadji, M [1 ]
Gomez-Fernandez, C [1 ]
Ganjei-Azar, P [1 ]
Morales, AR [1 ]
机构
[1] Univ Miami, Jackson Mem Hosp, Dept Pathol, Miami, FL 33136 USA
关键词
breast cancer; estrogen receptor; progesterone receptor; 1D5; antibody; immunohistochemistry; quantitation;
D O I
10.1309/4WV79N2GHJ3X1841
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Paraffin sections or fine-needle aspiration smears from 5,993 cases of invasive mammary carcinomas were assessed immunohistochemically for estrogen. receptor (ER; 1D5) and progesterone receptor (PR; 636) expression. Staining pattern and intensity were correlated with histologic subtypes and nuclear grades of tumors. Positive nuclear staining for ER and PR was observed in 75% and 55% of invasive carcinomas, respectively. In 92% of ER+ cases, diffuse and uniform staining of most tumor cells was observed. In the remaining 8%, a focal ER reaction was seen, usually because of inadequate fixation. In 21% of PR+ tumors, the reaction was heterogeneous or focal but unrelated to fixation. There were no ER-, PR+ tumors. All pure tubular, colloid, and infiltrating lobular carcinomas were ER+. All medullary, apocrine, and metaplastic and most high-nuclear-grade carcinomas were ER-. With monoclonal antibody 1D5 and antigen retrieval, immunohistochemical reaction, for ER in breast cancer usually is an all-or-none phenomenon; therefore, quantitation of results is unnecessary. Despite antigen retrieval, inadequate fixation can cause false-negative results; evaluation of internal positive control samples is imperative. ER positivity and negativity are predictable in certain histologic types and nuclear grades of breast cancer. The reaction for PR can be heterogeneous or focal.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 18 条
  • [1] CYTOGENETIC HETEROGENEITY AND HISTOLOGIC TUMOR-GROWTH PATTERNS IN PROSTATIC-CANCER
    ALERS, JC
    KRIJTENBURG, PJ
    VISSERS, CJ
    BOSMAN, FT
    VANDERKWAST, TH
    VANDEKKEN, H
    [J]. CYTOMETRY, 1995, 21 (01): : 84 - 94
  • [2] Allred DC, 1998, MODERN PATHOL, V11, P155
  • [3] Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients
    Barnes, DM
    Harris, WH
    Smith, P
    Millis, RR
    Rubens, RD
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 (09) : 1445 - 1451
  • [4] Clark GM, 1997, P AN M AM SOC CLIN, V16, P129
  • [5] Diallo R, 2001, J PATHOL, V193, P27, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH747>3.0.CO
  • [6] 2-H
  • [7] MOLECULAR ASPECTS OF ESTROGEN-RECEPTOR VARIANTS IN BREAST-CANCER
    FUQUA, SAW
    WOLF, DM
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1995, 35 (03) : 233 - 241
  • [8] Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma
    Goldstein, NS
    Ferkowicz, M
    Odish, E
    Mani, A
    Hastah, F
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (01) : 86 - 92
  • [9] A NEW IMMUNOHISTOCHEMICAL ANTIBODY FOR THE ASSESSMENT OF ESTROGEN-RECEPTOR STATUS ON ROUTINE FORMALIN-FIXED TISSUE SAMPLES
    GOULDING, H
    PINDER, S
    CANNON, P
    PEARSON, D
    NICHOLSON, R
    SNEAD, D
    BELL, J
    ELSTON, CWE
    ROBERTSON, JF
    BLAMEY, RW
    ELLIS, IO
    [J]. HUMAN PATHOLOGY, 1995, 26 (03) : 291 - 294
  • [10] Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    Harvey, JM
    Clark, GM
    Osborne, CK
    Allred, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1474 - 1481